Olmesartan medoxomil, a newly developed angiotensin ii type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats

Sho Ichi Yamagishi, M. Takeuchi, H. Inoue

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Although the molecular mechanisms for the development and progression of diabetic nephropathy are not fully understood, the formation of advanced glycation end products (AGEs) and activation of the renin-angiotensin system (RAS) have been considered to be the main factors participating in the pathogenesis of diabetic nephropathy. However, functional cross-talk between AGEs and the RAS remains to be elucidated. In this study, we examined the effects of oral administration of olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, on renal damage in AGE-treated rats. Administration of olmesartan medoxomil significantly inhibited the increase of systolic and diastolic blood pressure levels and urinary N-acetyl-β-D-glucosaminidase activity in exogenously AGE-injected rats. Furthermore, olmesartan medoxomil treatment also prevented glomerulosclerosis in AGE-treated rats. These results indicate that exogenous AGE treatment could induce renal damage via the activation of the RAS. Our study suggests that olmesartan medoxomil could be a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs.

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalDrugs under Experimental and Clinical Research
Volume31
Issue number2
Publication statusPublished - 2005 Dec 1

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)

Cite this